drugset / Trial / NCT00617877

Antihypertensive Response to Losartan and Genetic Polymorphisms

NCT00617877

Completed 800 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.

Timeline

Start
2005-03
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 100 mg
Background Hydrochlorothiazide Unknown 25 mg

Indications